title: Use of olprinone, a phosphodiesterase III inhibitor, in an asthmatic patient.
abstract: Phosphodiesterase (PDE) III exists in airway smooth muscles. In addition, PDEIII inhibitors have been suggested to relax airway smooth muscle by increasing intracellular cAMP concentrations. We report a successful use of olprinone, a PDEIII inhibitor, for treatment of an asthmatic attack. A 15-year-old male patient treated with oral theophylline 400 mg x d(-1) was anesthetized with propofol, fentanyl and ketamine for knee joint surgery. Immediately after tracheal intubation, an asthma attack occurred with peak airway pressure (Paw)>40 cmH2O. Thus, propofol 20 mg was additionally given to increase anesthetic depth, and Paw gradually decreased to 30 cmH2O. In addition, we started monitoring bronchial cross-sectional area using a superfine fiberoptic bronchoscopic method previously reported. However, as Paw did not further decrease for 30 min, olprinone was intravenously infused (10 microg x kg(-1) x 10 min(-1) + 0.3 microg x kg(-1) x min(-1), total 5 mg). Olprinone infusion rapidly decreased peak Paw from 30 cmH2O to 24 cmH2O and increased bronchial cross-sectional area by 50%. These findings suggest that olprinone produced bronchodilation.
authors: Department of Anesthesiology, University of Hirosaki School of Medicine, Japan. masuika@cc.hirosaki-u.ac.jp
authors: K
authors: K
authors: Hirota
authors: S
authors: S
authors: Kabara
authors: H
authors: H
authors: Hashimoto
authors: H
authors: H
authors: Ishihara
authors: A
authors: A
authors: Matsuki
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000328:Adult; D000403:Airway Resistance / Q000502:physiology; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001999:Bronchoscopy; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007432:Intraoperative Period; D008170:Lung Compliance / Q000502:physiology; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*
chemical_list: D018927:Anti-Asthmatic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D011728:Pyridones; C059498:olprinone; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3